An interrelationship between neuroinflammation and progression of Alzheimer's disease (AD) / A inter-relação entre a neuroinflamação e a progressão da Doença de Alzheimer (DA)

Authors

  • Glesley Vito Lima Lemos Brazilian Journals Publicações de Periódicos, São José dos Pinhais, Paraná
  • Leidson Rodrigo Teixeira Ribeiro
  • Thiago Fraga Habib
  • Conceição Neves Ferraz
  • Paulo Roberto Santana de Melo
  • Fernando de Mello Almada Giuffrida
  • Aníbal de Freitas Santos Júnior
  • Bruno Veloso Cerqueira

DOI:

https://doi.org/10.34117/bjdv7n4-570

Keywords:

Alzheimer's disease, neuroinflammatory cytokines.

Abstract

Alzheimer's disease (AD) is among the major neurodegenerative diseases in the world, characterized by progressive decline in cognitive abilities, behavioral abnormalities and functional loss in daily activities. Several studies indicate the effectiveness of using biomarkers as a diagnostic source of the disease, as well as suggesting the analysis of inflammatory cytokines as accompanying factors. There are several inflammatory cytokines that are well described in the pathogenesis of AD, such as Interleukin-6 (IL-6), IL-1ß, tumor necrosis factor (TNF-?), oxidative stress, among others. Some chemokines, although presenting a protective and modulating character of neuroinflammation, also appear as proinflammatory proteins, depending on the course of the disease, such as CX3C. This review considers that neuroinflammation has a degenerative character in the Central Nervous System (CNS), and understands that it needs more evidence regarding these data, especially in the pharmacotherapy question.

References

Kawai U, Uchida N, Oono M, Fujita-Nakata M, Nakanishi M, Sanada M, et al. Relationship of systemic inflammation and cellular immunity with advancement of cognitive decline in patients with Alzheimer’s disease. Clin Exp Neuroimmunol. 2018;9(3):182–8.

Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Lamb BT. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimer’s Dement Transl Res Clin Interv [Internet]. 2018;(September):1–16. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2352873718300490

Cerquera-Jaramillo MA, Nava-Mesa MO, González-Reyes RE, Tellez-Conti C, De-la-Torre A. Visual Features in Alzheimer ’ S Disease?: From Basic Mechanisms To Clinical Overview. Neural Plast. 2018;2018:1–21.

Bagyinszky E, Giau V Van, Shim K, Suk K, An SSA, Kim SY. Role of inflammatory molecules in the Alzheimer’s disease progression and diagnosis. J Neurol Sci [Internet]. 2017;376:242–54. Available from: http://dx.doi.org/10.1016/j.jns.2017.03.031

Dias ES, Moura HFS, Tannus CDA, Pacheco MP, Lemos GVL, Ribeiro LRT, et al. Conflitos emocionais em cuidadores de pacientes com doença de alzheimer. Brazilian J Dev. 2020;6(5):29036–50.

Magalhães TNC, Weiler M, Teixeira CVL, Hayata T, Moraes AS, Boldrini VO, et al. Systemic Inflammation and Multimodal Biomarkers in Amnestic Mild Cognitive Impairment and Alzheimer’s Disease. Mol Neurobiol. 2018;55(7):5689–97.

Liu C, Cui G, Zhu M, Kang X, Guo H. Neuroinflammation in Alzheimer’s disease: Chemokines produced by astrocytes and chemokine receptors. Int J Clin Exp Pathol. 2014;7(12):8342–55.

Walker KA, Windham BG, Knopman DS, Jr CRJ, Jr THM, Selvin E, et al. Un co rre cte d Au tho r P roo f Un co rre cte d Au tho r P f. 2018;

Hopp SC, Lin Y, Oakley D, Roe AD, Devos SL, Hanlon D, et al. The role of microglia in processing and spreading of bioactive tau seeds in Alzheimer’s disease 11 Medical and Health Sciences 1109 Neurosciences. J Neuroinflammation. 2018;15(1):1–15.

Ng A, Tam WW, Zhang MW, Ho CS, Husain SF, McIntyre RS, et al. IL-1?, IL-6, TNF- ? and CRP in Elderly Patients with Depression or Alzheimer’s disease: Systematic Review and Meta-Analysis. Sci Rep. 2018;8(1):1–12.

Ahmad MH, Fatima M, Mondal AC. Influence of microglia and astrocyte activation in the neuroinflammatory pathogenesis of Alzheimer ’ s disease?: Rational insights for the therapeutic approaches. J Clin Neurosci [Internet]. 2018; Available from: https://doi.org/10.1016/j.jocn.2018.10.034

Dong X, Zhang L, Meng Q, Gao Q. Association Between Interleukin-1A, Interleukin-1B, and Bridging integrator 1 Polymorphisms and Alzheimer’s Disease: a standard and Cumulative Meta-analysis. Mol Neurobiol [Internet]. 2017;54(1):736–47. Available from: http://dx.doi.org/10.1007/s12035-015-9683-3

Huang C, Hsu S, Tsai S, Chen N, Liu M, Lee C. Genetic effect of interleukin-1 beta ( C-511T ) polymorphism on the structural covariance network and white matter integrity in Alzheimer ’ s disease. J Neuroinflammation [Internet]. 2017;1–13. Available from: http://dx.doi.org/10.1186/s12974-017-0791-z

Abd Rachman Isnadi MF, Chin VK, Abd Majid R, Lee TY, Atmadini Abdullah M, Bello Omenesa R, et al. Critical Roles of IL-33/ST2 Pathway in Neurological Disorders. Mediators Inflamm. 2018;2018.

Xiong Z, Thangavel R, Kempuraj D, Yang E, Zaheer S, Zaheer A. Alzheimer’s disease: Evidence for the expression of interleukin-33 and its receptor ST2 in the brain. J Alzheimer’s Dis. 2014;40(2):297–308.

Wu YY, Hsu JL, Wang HC, Wu SJ, Hong CJ, Cheng IHJ. Alterations of the Neuroinflammatory Markers IL-6 and TRAIL in Alzheimer’s Disease. Dement Geriatr Cogn Dis Extra. 2015;5(3):424–34.

Shahrokhi VM, Ravari A, Mirzaei T, Asadikaram G, Arababadi MK. IL-17A and IL-23?: plausible risk factors to induce age-associated inflammation in Alzheimer ’ s disease. Immunol Invest [Internet]. 2018;00(00):1–11. Available from: https://doi.org/10.1080/08820139.2018.1504300

Sumbria R, Chang R, Yee K-L. Tumor necrosis factor ? Inhibition for Alzheimer’s Disease. J Cent Nerv Syst Dis [Internet]. 2017;9(0):0–4. Available from: http://insights.sagepub.com/tumor-necrosis-factor--inhibition-for-alzheimers-disease-article-a6334

Dezfulian M. A new Alzheimer’s disease cell model using B cells to induce beta amyloid plaque formation and increase TNF alpha expression. Int Immunopharmacol [Internet]. 2018;59(October 2017):106–12. Available from: https://doi.org/10.1016/j.intimp.2018.04.012

Ekert JO, Gould RL, Reynolds G, Howard RJ. TNF alpha inhibitors in alzheimer’s disease: A systematic review. Int J Geriatr Psychiatry. 2018;33(5):688–94.

Azizi G, Khannazer N, Mirshafiey A. American Journal of Alzheimer ’ s Disease and Other Dementias The Potential Role of Chemokines in Alzheimer ’ s Disease Pathogenesis. 2014;

Chen P, Zhao W, Guo Y, Xu J, Yin M. CX3CL1 / CX3CR1 in Alzheimer ’ s Disease?: A Target for Neuroprotection. 2016;2016.

Martin E. ScienceDirect Complex role of chemokine mediators in animal models of Alzheimer ’ s Disease. 2018;1–7.

Burmeister AR, Marriott I. The Interleukin-10 Family of Cytokines and Their Role in the CNS. Front Cell Neurosci. 2018;12(November):458.

Boza-Serrano A, Yang Y, Paulus A, Deierborg T. Innate immune alterations are elicited in microglial cells before plaque deposition in the Alzheimer’s disease mouse model 5xFAD. Sci Rep [Internet]. 2018;8(1):1–16. Available from: http://dx.doi.org/10.1038/s41598-018-19699-y

Asselineau D, Benlhassan K, Arosio B, Mari D, Ferri E, Casati M, et al. Interleukin-10 Production in Response to Amyloid-? Differs between Slow and Fast Decliners in Patients with Alzheimer’s Disease. J Alzheimer’s Dis. 2015;46(4):837–42.

Published

2021-04-23

How to Cite

Lemos, G. V. L., Ribeiro, L. R. T., Habib, T. F., Ferraz, C. N., de Melo, P. R. S., Giuffrida, F. de M. A., Júnior, A. de F. S., & Cerqueira, B. V. (2021). An interrelationship between neuroinflammation and progression of Alzheimer’s disease (AD) / A inter-relação entre a neuroinflamação e a progressão da Doença de Alzheimer (DA). Brazilian Journal of Development, 7(4), 41689–41701. https://doi.org/10.34117/bjdv7n4-570

Issue

Section

Original Papers